PROM1 and neoplasm: Even complete loss of CD133, a marker commonly used to enrich TICs in PDAC and other solid tumors (Singh et al, 2003; Hermann et al, 2007; O'Brien et al, 2007; Ricci‐Vitiani et al, 2007), was not associated with decreased tumor‐forming potential (Fig 3F; Appendix Table S6).